2020
DOI: 10.3389/fmicb.2020.02085
|View full text |Cite
|
Sign up to set email alerts
|

Tedizolid-Rifampicin Combination Prevents Rifampicin-Resistance on in vitro Model of Staphylococcus aureus Mature Biofilm

Abstract: Staphylococcus aureus infections associated with implanted medical devices are difficult to treat and require long-lasting antibiotic therapies, especially when device removal is not possible or easy such as in the case of joint prostheses. Biofilm formation is a major cause of treatment failure and infection recurrence. This study aimed to test, for the first time, the in vitro combination of tedizolid plus rifampicin on methicillin-sensitive (MSSA ATCC 6538) and methicillin-… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8
1
1

Relationship

0
10

Authors

Journals

citations
Cited by 13 publications
(7 citation statements)
references
References 51 publications
0
7
0
Order By: Relevance
“…Moreover, we showed in murine infected bone defect models that incorporating rifampin and sitafloxacin into 3D-printed calcium-phosphate resorbable scaffold was more antimicrobial and osteoconductive in a single-stage revision versus conventional gentamicin ALBC in a two-stage revision [ 51 ]. We chose tedizolid as an alternative antibiotic based on similar biofilm eradication activity [ 52 ]. As expected, the O -phenyl carbamate sitafloxacin-conjugated BP and HBP demonstrated substantial biofilm eradication potential against prototypic MSSA and MRSA stains ( Figure 7 and Figure 8 ).…”
Section: Discussionmentioning
confidence: 99%
“…Moreover, we showed in murine infected bone defect models that incorporating rifampin and sitafloxacin into 3D-printed calcium-phosphate resorbable scaffold was more antimicrobial and osteoconductive in a single-stage revision versus conventional gentamicin ALBC in a two-stage revision [ 51 ]. We chose tedizolid as an alternative antibiotic based on similar biofilm eradication activity [ 52 ]. As expected, the O -phenyl carbamate sitafloxacin-conjugated BP and HBP demonstrated substantial biofilm eradication potential against prototypic MSSA and MRSA stains ( Figure 7 and Figure 8 ).…”
Section: Discussionmentioning
confidence: 99%
“…Staphylococcus aureus is categorized into two groups, methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) ( Ahmed and Mukherjee, 2018 ). Which is based on the well-known differences of the mec A gene conferred to the pathogen, and the significant difference of the biofilm formation between MRSA and MSSA strains ( Gidari et al, 2020 ). MRSA is responsible for most global Staphylococcus aureus bacteremia cases, and MRSA infection is related to poorer clinical outcomes than MSSA ( Hassoun et al, 2017 ).…”
Section: Introductionmentioning
confidence: 99%
“…The azAbx included were rifampicin, erythromycin, linezolid, and ciprofloxacin, which are treatment options for S. aureus infections. [63][64][65][66] The selected antibiotics have chemical compositions that range in hydrophobicity, polarity, size, and charge to examine how these factors affect their ultimate accumulation into phagosomes. Furthermore, we also tested two variations of ciprofloxacin: one containing the azide modification on the pyridinyl group that has an overall net negative charge and another that has an additional ester modification to return the molecule to a net neutral charge.…”
Section: Resultsmentioning
confidence: 99%